Related Experiment Video
Updated: May 14, 2026
07:55
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Hypoxic Tumor Microenvironment Targeting: Opportunities and Challenges for Pancreatic Cancer Immunotherapy
Raefa Abou Khouzam1, Shaima Salman2, Jerome Thiery3
1Thumbay Research Institute for Precision Medicine, Gulf Medical University, Ajman 4184, United Arab Emirates.
International Journal of Molecular Sciences
|May 13, 2026
Summary
Pancreatic cancer (PDAC) is deadly due to tumor hypoxia, which hinders immunotherapy. Targeting hypoxia could improve responses to immune checkpoint inhibitors (ICIs) by making tumors more responsive.
Area of Science:
- Oncology
- Immunology
- Cancer Biology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis and resistance to therapies.
- Tumor hypoxia, driven by desmoplasia and aberrant vasculature, creates an immunosuppressive tumor microenvironment (TME).
- Hypoxia-inducible factors (HIFs) stabilize in hypoxic conditions, promoting immune exclusion and TME acidification, contributing to PDAC's resistance to immune checkpoint inhibitors (ICIs).
Purpose of the Study:
- To review the mechanistic role of hypoxia in PDAC immune evasion.
- To provide an update on therapeutic strategies targeting hypoxia.
- To evaluate the potential of hypoxia modulation to enhance ICI efficacy in PDAC.
Main Methods:
- Literature review of PDAC, tumor hypoxia, and immunotherapy.
- Analysis of hypoxia's impact on the TME and immune response.
- Evaluation of therapeutic approaches targeting hypoxia, including HIF inhibition, hypoxia-activated prodrugs, and vascular normalization.
Main Results:
- Hypoxia is a key driver of the ICI-refractory TME in PDAC.
- PDAC tumors exhibit variable hypoxic levels, correlating with survival and immune suppression.
- Emerging therapies targeting hypoxia show potential for synergistic effects with ICIs.
Conclusions:
- Targeting tumor hypoxia is a promising strategy to overcome ICI resistance in PDAC.
- Hypoxia biomarkers, such as gene signatures, are needed for precision hypoxia modulation.
- Precision hypoxia modulation may convert immune-cold PDAC into an ICI-responsive disease.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...